アフターアワーズ： 41.75

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA) 最新ニュース

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA) 最新ニュース

Unveiling 7 Analyst Insights On Avidity Biosciences - Benzinga

Rhumbline Advisers Grows Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Avidity Biosciences executive sells over $4.5 million in company stock By Investing.com - Investing.com Australia

Avidity Biosciences executive sells over $4.5 million in company stock - Investing.com

Avidity Biosciences executive sells over $4.5 million in company stock By Investing.com - Investing.com UK

Certain Restricted stock units of Avidity Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2024. - Marketscreener.com

(RNA) On The My Stocks Page - Stock Traders Daily

Avidity Biosciences’ $300 Million Common Stock Offering - Global Legal Chronicle

Cowen AND Company LLC Sells 500,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Avidity Biosciences (NASDAQ:RNA) Given Overweight Rating at Cantor Fitzgerald - MarketBeat

Bank of New York Mellon Corp Has $14.87 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month - StockTitan

U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail

TSX Consumer Staples Capped Index (TTCS) QuotePress Release - The Globe and Mail

TSX Materials Capped Index (TTMT) QuotePress Release - The Globe and Mail

2 Standout Biotech Stocks With 32% to 63% Upside - TradingView

KBW Finsec Dividend Yield Index (KDX) QuotePress Release - The Globe and Mail

PHLX Canadian Dollar (XDC) QuotePress Release - The Globe and Mail

Privium Fund Management B.V. Raises Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $55.86 Consensus Price Target from Analysts - MarketBeat

Barclays Initiates Coverage of Avidity Biosciences (RNA) with Overweight Recommendation - MSN

Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings) - LongPort

Avidity Biosciences (NASDAQ:RNA) Shares Up 2.4% - MarketBeat

Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings) - Benzinga

Avidity Biosciences to Participate in Upcoming Investor Conferences – Company Announcement - Financial Times

Avidity Biosciences (NASDAQ:RNA) Research Coverage Started at Barclays - MarketBeat

Avidity Biosciences, Inc. (NASDAQ:RNA) Stock Holdings Decreased by Raymond James & Associates - MarketBeat

Life Science Cares San Diego Scales Partnership with Avidity Biosciences Through Life Science Shares Program - Yahoo Finance UK

Life Science Cares San Diego Scales Partnership with Avidity Biosciences Through Life Science Shares Program - Business Wire

29,992 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Acquired by EFG Asset Management North America Corp. - MarketBeat

Evercore ISI Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $53.00 - MarketBeat

Avidity Offering Nabs $345M - San Diego Business Journal

Avidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 5,000 Shares - Defense World

Assenagon Asset Management S.A. Buys Shares of 48,969 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Avidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 5,000 Shares - MarketBeat

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times

Avidity Biosciences (NASDAQ:RNA) Trading Down 3.3% - MarketBeat

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA - Yahoo Finance

Buoyed by muscular dystrophy data, Avidity raises $345m - pharmaphorum

Firm Advises Avidity Biosciences on IP Matters Related to Public Offering - Wilson Sonsini

Avidity Biosciences raises $345 million for RNA therapeutics - The Pharma Letter

Avidity Biosciences Announces Closing of Upsized Public Offering - GuruFocus.com

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares – Company AnnouncementFT.com - Financial Times

This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now? - MarketBeat

Avidity Biosciences (NASDAQ:RNA) Sees Large Volume Increase - Defense World

Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings - BioCentury

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders (RNA) - Seeking Alpha

Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress - Longview News-Journal

Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com

Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com

Avidity Biosciences (NASDAQ:RNA) Sees Large Volume Increase - MarketBeat

Latham & Watkins Advises Avidity Biosciences on Upsized Public Offering of Common Stock - Latham & Watkins LLP -

Research Analysts Offer Predictions for Avidity Biosciences, Inc.'s FY2024 Earnings (NASDAQ:RNA) - MarketBeat

FY2024 EPS Estimates for Avidity Biosciences, Inc. (NASDAQ:RNA) Raised by Analyst - Defense World

Avidity Biosciences, Inc. Forecasted to Post FY2024 Earnings of ($2.68) Per Share (NASDAQ:RNA) - Defense World

Avidity Biosciences to Participate in Upcoming Investor Conference - Longview News-Journal

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - Financial Times

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - GuruFocus.com

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - StockTitan

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - PR Newswire

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $44.99 - MarketBeat

Avidity Biosciences plans $250 million stock offering By Investing.com - Investing.com Australia

Q3 2024 EPS Estimates for Avidity Biosciences, Inc. Boosted by Leerink Partnrs (NASDAQ:RNA) - MarketBeat

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More - MSN

Q3 2024 EPS Estimates for Avidity Biosciences, Inc. Lifted by Analyst (NASDAQ:RNA) - Defense World

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67 - Simply Wall St

Avidity Biosciences plans $250 million stock offering - Investing.com

RNAに似た銘柄